“…The cov-OPS:DEX particles used in this study can easily pass through a 27-gauge needle, and can place the drug loaded particles into vitreous at the posterior. Due to the fact that vitreous water exits mainly through the retina into the choroid (over 80%), (Moseley et al, 1984) the drug placed in the posterior vitreous would be the most effective for macular diseases and would bring the least complications, such as high IOP and cataract. From the current in vitro drug release, the covalent conjugation of Dex to pSiO 2 led to a sustained Dex release for at least 90 days, with a mean concentration of 2480±2549 ng/mL during first 9 days, 224±141 ng/mL from day 14 to day 40, and 24±15 ng/mL during the last segment of 45 days (from day 45 to day 90).…”